Administration of dendritic cells partially matured in vitro for the treatment of tumors
AssigneeNorthwest Biotherapeutics, Inc.
InventorMarnix L. Bosch
Life of this patent
Estimating the term…
Loading patent…
AssigneeNorthwest Biotherapeutics, Inc.
InventorMarnix L. Bosch
Estimating the term…
The present invention provides populations of cells comprising partially matured dendritic cells that can be used for administration individuals having a tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 1 to about 10 hours, or more, efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in the lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNFα and IL-12) and contact T cells inducing a substantial anti-tumor immune response.
A method for producing an anti-tumor immune response comprising administration to an individual with a cancerous tumor a cell population comprising partially matured dendritic cells that have been induced to initiate maturation in vitro, wherein the partially matured dendritic cells take up and process antigen in vivo and are enabled to induce an anti-tumor immune response subsequent to administration to the individual.
A composition comprising partially mature dendritic cells combined with a pharmaceutically acceptable carrier for in vivo administration, wherein the partially mature dendritic cells have been contacted in vitro with a dendritic cell maturation agent.
Dependencies are inferred from the claim text.